Key facts
- Levels Diagnostics’s last known valuation is $940K (Jan 2022).
- It has raised $470K; the latest was Later Stage VC in Jan 2026.
- Notable investors include Imec.istart, Hezelburcht, Libertatis Ergo Holding (LEH), LifeSciences@Work, Merck Accelerator Program — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Levels Diagnostics
- ·The full record, as it builds
Funding rounds
No funding rounds for Levels Diagnostics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Levels Diagnostics
Developer of a diagnostic tool designed to advance healthcare through the discovery of clinically relevant biomarkers. The company offers end-to-end biomarker research, including clinical trial design with medical experts, resolution proteomic screening, rigorous in-house data analysis, and the development of diagnostic tests for early disease detection, enabling healthcare researchers and clinicians to identify conditions earlier and support more informed clinical decision-making.
- Sector
- Healthcare
- HQ
- Leiden, Netherlands
- Founded
- 2017
- Employees
- 6
- Website
- levels.bio/
- Ownership
- Privately Held (backing)
Levels Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Levels Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Levels Diagnostics in its N-PORT filings yet. We sweep new filings monthly.